49
Participants
Start Date
June 21, 2017
Primary Completion Date
March 6, 2023
Study Completion Date
March 6, 2023
Fludarabine
30 mg/m2 by vein on Days -5 to -3.
Cyclophosphamide
300 mg/m2 by vein on Days -5 to -3.
Mesna
300 mg/m2 by vein on Days -5 to -3 before and after the cyclophosphamide dose.
iC9/CAR.19/IL15-Transduced CB-NK Cells
"Infusion of iC9/CAR.19/IL15-transduced CB-NK cells on Day 0 by vein.~Starting dose: 10E5"
AP1903
If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.
University of Texas MD Anderson Cancer Center, Houston
M.D. Anderson Cancer Center
OTHER